Imaging and Biomarkers in Early Alzheimer's Disease and Mild Cognitive Impairment

A major focus of research on aging and dementia pertains to the prediction of future cognitive decline. Toward this end, several longitudinal studies are under way that are designed to explore early predictors of cognitive impairment. Neuroimaging techniques and biomarkers have shown promise in this application. Ultimately, it is likely that the use of a combination of neuroimaging and chemical biomarkers will be involved in predicting the development of dementia and Alzheimer's disease (AD).

[1]  C. Paúl,et al.  Education, leisure activities and cognitive and functional ability of Alzheimer's disease patients: A follow-up study , 2013, Dementia & neuropsychologia.

[2]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[3]  Nick C Fox,et al.  Brain atrophy progression measured from registered serial MRI: Validation and application to alzheimer's disease , 1997, Journal of magnetic resonance imaging : JMRI.

[4]  G. Fein,et al.  Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.

[5]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[6]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[7]  Mayo Clinic,et al.  PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .

[8]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[9]  K. Blennow,et al.  Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and β-amyloid metabolism in Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[10]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[11]  Sheryl Zimmerman,et al.  The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. , 2002, Annual review of public health.

[12]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[13]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[14]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[15]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[16]  C. Jack,et al.  DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment , 2005, Neurology.

[17]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[18]  P. Murali Doraiswamy,et al.  Alzheimer's Disease: 100 Years of Progress , 2005 .

[19]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[20]  R. Petersen,et al.  Mild cognitive impairment , 2006, The Lancet.

[21]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[22]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[23]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[24]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[25]  B. Winblad,et al.  Safety and efficacy of galantamine in subjects with mild cognitive impairment , 2008, Neurology.

[26]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[27]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[28]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[29]  Matthew L Senjem,et al.  Functional magnetic resonance imaging changes in amnestic and nonamnestic mild cognitive impairment during encoding and recognition tasks , 2009, Journal of the International Neuropsychological Society.

[30]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.